Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMvigor210
  • Sponsors Roche
  • Most Recent Events

    • 29 Aug 2018 This trial has been completed in Germany (end date: 2018-05-23), according to European Clinical Trials Database.
    • 23 Jul 2018 New trial record
    • 05 Jun 2018 Results of long-term efficacy from the phase 2 study IMvigor210 (both patient populations: Cohort 1: NCT02951767, n=119 and Cohort 2: NCT02108652, n=310; as of 12 Jul 2017), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top